336 related articles for article (PubMed ID: 18829563)
1. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
2. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies.
Cardarelli PM; Rao-Naik C; Chen S; Huang H; Pham A; Moldovan-Loomis MC; Pan C; Preston B; Passmore D; Liu J; Kuhne MR; Witte A; Blanset D; King DJ
Cancer Immunol Immunother; 2010 Feb; 59(2):257-65. PubMed ID: 19657637
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.
Pietersz GA; Wenjun L; Sutton VR; Burgess J; McKenzie IF; Zola H; Trapani JA
Cancer Immunol Immunother; 1995 Jul; 41(1):53-60. PubMed ID: 7543822
[TBL] [Abstract][Full Text] [Related]
4. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.
Stieglmaier J; Bremer E; Kellner C; Liebig TM; ten Cate B; Peipp M; Schulze-Koops H; Pfeiffer M; Bühring HJ; Greil J; Oduncu F; Emmerich B; Fey GH; Helfrich W
Cancer Immunol Immunother; 2008 Feb; 57(2):233-46. PubMed ID: 17665197
[TBL] [Abstract][Full Text] [Related]
5. Structural characterization of a human Fc fragment engineered for lack of effector functions.
Oganesyan V; Gao C; Shirinian L; Wu H; Dall'Acqua WF
Acta Crystallogr D Biol Crystallogr; 2008 Jun; 64(Pt 6):700-4. PubMed ID: 18560159
[TBL] [Abstract][Full Text] [Related]
6. Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies.
Zekri L; Hagelstein I; Märklin M; Klimovich B; Christie M; Lindner C; Kämereit S; Prakash N; Müller S; Stotz S; Maurer A; Greve C; Schmied B; Atar D; Rammensee HG; Jung G; Salih HR
Sci Transl Med; 2024 Mar; 16(737):eadh1988. PubMed ID: 38446900
[TBL] [Abstract][Full Text] [Related]
7. Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma.
Takheaw N; Sittithumcharee G; Kariya R; Kasinrerk W; Okada S
Cancer Immunol Immunother; 2021 Jun; 70(6):1557-1567. PubMed ID: 33215253
[TBL] [Abstract][Full Text] [Related]
8. CD19 as an attractive target for antibody-based therapy.
Hammer O
MAbs; 2012; 4(5):571-7. PubMed ID: 22820352
[TBL] [Abstract][Full Text] [Related]
9. Antibody-based therapy of leukaemia.
Morris JC; Waldmann TA
Expert Rev Mol Med; 2009 Sep; 11():e29. PubMed ID: 19788782
[TBL] [Abstract][Full Text] [Related]
10. Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockade.
Schewe DM; Vogiatzi F; Münnich IA; Zeller T; Windisch R; Wichmann C; Müller K; Bhat H; Felix E; Mougiakakos D; Bruns H; Lenk L; Valerius T; Humpe A; Peipp M; Kellner C
Hemasphere; 2024 Feb; 8(2):e48. PubMed ID: 38435424
[TBL] [Abstract][Full Text] [Related]
11. ABBV-319: A CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies.
Chang CA; Emberley E; D'Souza AL; Zhao W; Cosgrove C; Parrish KE; Mitra D; Payson E; Oleksijew A; Ellis P; Rodriguez L; Duggan R; Hrusch C; Lasko L; Assaily W; Zheng P; Liu W; Hernandez A; McCarthy K; Zhang Z; Rha G; Cao Z; Li Y; Perng O; Campbell J; Zhang G; Curran TS; Bruncko M; Marvin CC; Hobson AD; McPherson M; Uziel T; Pysz MA; Zhao X; Bankovich A; Hayflick J; McDevitt M; Freise KJ; Morgan-Lappe S; Purcell JW
Blood; 2024 May; ():. PubMed ID: 38701407
[TBL] [Abstract][Full Text] [Related]
12. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
Zammarchi F; Corbett S; Adams L; Tyrer PC; Kiakos K; Janghra N; Marafioti T; Britten CE; Havenith CEG; Chivers S; D'Hooge F; Williams DG; Tiberghien A; Howard PW; Hartley JA; van Berkel PH
Blood; 2018 Mar; 131(10):1094-1105. PubMed ID: 29298756
[TBL] [Abstract][Full Text] [Related]
13. STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.
Dahal LN; Dou L; Hussain K; Liu R; Earley A; Cox KL; Murinello S; Tracy I; Forconi F; Steele AJ; Duriez PJ; Gomez-Nicola D; Teeling JL; Glennie MJ; Cragg MS; Beers SA
Cancer Res; 2017 Jul; 77(13):3619-3631. PubMed ID: 28512240
[TBL] [Abstract][Full Text] [Related]
14. CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression.
Meetze K; Mehta NK; Li B; Michaelson JS; Baeuerle PA
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586770
[TBL] [Abstract][Full Text] [Related]
15. Application of Computational Techniques in Antibody Fc-Fused Molecule Design for Therapeutics.
Ng CL; Lim TS; Choong YS
Mol Biotechnol; 2024 Apr; 66(4):568-581. PubMed ID: 37742298
[TBL] [Abstract][Full Text] [Related]
16. 99mTc-CD19 monoclonal antibody is not useful for imaging of B cell non-Hodgkin's lymphoma.
Vervoordeldonk SF; Heikens J; Goedemans WT; Merle PA; von dem Borne AE; van Royen EA; Slaper-Cortenbach IC; van Oers RH
Cancer Immunol Immunother; 1996 Jun; 42(5):291-6. PubMed ID: 8706051
[TBL] [Abstract][Full Text] [Related]
17. Preclinical study of CD19 detection methods post tafasitamab treatment.
Ilieva K; Eberl M; Jaehrling J; Blair D; Patra-Kneuer M; Boxhammer R; Alvarez Arias D; Heitmüller C
Front Immunol; 2023; 14():1274556. PubMed ID: 37928552
[TBL] [Abstract][Full Text] [Related]
18. Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies.
Dong Z; Song JY; Thieme E; Anderson A; Oh E; Cheng WA; Kuang BZ; Lee V; Zhang T; Wang Z; Szymura S; Smith DL; Zhang J; Nian W; Zheng X; He F; Zhou Q; Cha SC; Danilov AV; Qin H; Kwak LW
Blood Adv; 2023 Mar; 7(6):918-932. PubMed ID: 36469551
[TBL] [Abstract][Full Text] [Related]
19. Human plasma cells engineered to secrete bispecifics drive effective
Hill TF; Narvekar P; Asher G; Camp N; Thomas KR; Tasian SK; Rawlings DJ; James RG
bioRxiv; 2023 Aug; ():. PubMed ID: 37662410
[TBL] [Abstract][Full Text] [Related]
20. Enhancing the Anti-tumor Potency of a Novel Siglec-15 Antibody by Engineering its Fc-mediated Effector Functions.
Ding H; Yao B; Ci L; Feng J; Ouyang P; Chen G; Hui X; Zhou D
J Immunother; 2023 Jun; 46(5):161-169. PubMed ID: 37103472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
